Tsubota Laboratory Incorporated AI Stock Analysis
Want to see JP:4890 full AI Analyst Report?
Tsubota Laboratory Incorporated (4890) AI Stock Analysis
Tsubota Laboratory Incorporated
(TSE/TYO:4890)
The score is primarily held down by weak financial performance—especially the severe 2026 revenue decline, deep losses, and sustained negative operating/free cash flow—despite a relatively low-debt balance sheet. Technical indicators also lean bearish with the stock trading below key moving averages and a negative MACD. Valuation provides limited support because the negative P/E is driven by losses and no dividend yield is available.
Tsubota Laboratory Incorporated (4890) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 5.67B
- Dividend Yield
- ―
- Average Volume (3M)
- 39.56K
- Price to Earnings (P/E)
- -8.4
- Beta (1Y)
- 0.37
- Revenue Growth
- -39.46%
- EPS Growth
- -317.84%
- Country
- Japan
- Employees
- 22
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Specialty Business Services
Tsubota Laboratory Incorporated Business Overview & Revenue Model
Company Description
Operating from Tokyo, Japan since its establishment in 2012, Tsubota Laboratory Incorporated is dedicated to the research and development of pharmaceutical products and medical devices, specifically targeting the treatment of myopia, dry eyes, and pr...
How the Company Makes Money
The company primarily makes money by commercializing ophthalmology-related offerings, which typically includes monetization from product and/or service sales tied to eye-care solutions and potentially revenues associated with research and development...
Tsubota Laboratory Incorporated Financial Statement Overview
Summary
Financials are dominated by a sharp 2026 deterioration: revenue collapsed (-85.3% YoY) with deeply negative profitability (net margin -381%) and continued cash burn. While the balance sheet is conservatively financed with low leverage and substantial equity, operating volatility and weak cash flow (negative operating cash flow in 2024–2026, including a very large outflow in 2026) significantly weaken overall financial quality.
Income Statement
27NegativeBalance Sheet
73PositiveCash Flow
18Very Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 390.58M | 200.02M | 1.36B | 673.53M | 954.69M | 640.92M |
| Gross Profit | 148.27M | 131.57M | 1.15B | -9.48M | 686.83M | 528.76M |
| EBITDA | -720.42M | -765.24M | 262.46M | -609.24M | 206.22M | 173.87M |
| Net Income | -693.63M | -761.82M | 205.77M | -641.32M | 90.18M | 153.32M |
Balance Sheet | ||||||
| Total Assets | 1.31B | 1.32B | 2.50B | 2.30B | 2.67B | 1.62B |
| Cash, Cash Equivalents and Short-Term Investments | 699.26M | 969.85M | 1.54B | 1.88B | 2.16B | 1.17B |
| Total Debt | 63.64M | 69.21M | 90.38M | 116.90M | 139.34M | 223.82M |
| Total Liabilities | 578.57M | 454.92M | 915.85M | 927.93M | 722.59M | 873.44M |
| Stockholders Equity | 733.83M | 863.86M | 1.59B | 1.37B | 1.95B | 744.35M |
Cash Flow | ||||||
| Free Cash Flow | 0 | -586.61M | -331.75M | -313.35M | -15.27M | 582.69M |
| Operating Cash Flow | 0 | -577.83M | -317.75M | -301.35M | 28.49M | 654.91M |
| Investing Cash Flow | 0 | -8.41M | -14.55M | -12.00M | -54.03M | -72.23M |
| Financing Cash Flow | 0 | 17.23M | -12.25M | 35.74M | 1.01B | -18.53M |
Tsubota Laboratory Incorporated Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4890, the sentiment is Negative. The current price of 233.00 is below the 20-day moving average (MA) of 246.50, below the 50-day MA of 260.36, and below the 200-day MA of 274.87, indicating a bearish trend. The MACD of -8.10 indicates Positive momentum. The RSI at 40.54 is Neutral, neither overbought nor oversold. The STOCH value of 43.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4890.
Tsubota Laboratory Incorporated Peers Comparison
Overall Rating
JP:339181Outperform
JP:764969Neutral
JP:998969Neutral
JP:354962Neutral
JP:334959.9Neutral- JP:489044Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:3391 | 81Outperform | JPY 1.13T | 19.41 | 7.13% | 1.91% | ― | ― |
| JP:7649 | 69Neutral | JPY 528.15B | 16.79 | 9.94% | 1.30% | 8.97% | -29.54% |
| JP:9989 | 69Neutral | JPY 452.96B | 14.37 | 11.15% | 3.43% | 4.32% | 0.18% |
| JP:3549 | 62Neutral | JPY 486.01B | 25.22 | ― | 0.29% | 12.54% | 15.87% |
| JP:3349 | 60Neutral | JPY 502.83B | 15.48 | ― | 1.31% | 8.99% | 3.61% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| JP:4890 | 44Neutral | JPY 6.13B | -8.36 | ― | ― | -39.46% | -317.84% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4890 | Tsubota Laboratory Incorporated | 233.00 | -100.00 | -30.03% | |
| JP:9989 | Sundrug Co | 3848.00 | -263.45 | -6.41% | |
| JP:7649 | Sugi Holdings Co | 1345.00 | -419.08 | -23.76% | |
| JP:3391 | TSURUHA Holdings | 2455.50 | -241.32 | -8.95% | |
| JP:3349 | COSMOS Pharmaceutical Corporation | 6236.00 | -1078.62 | -14.75% | |
| JP:3549 | KUSURI NO AOKI HOLDINGS CO.,LTD. | 5084.00 | 1137.96 | 28.84% |
Tsubota Laboratory Incorporated Corporate Events
Tsubota Laboratory Reports ¥491 Million Six-Month Revenue and Operating Loss
Tsubota Laboratory Incorporated, listed on the Tokyo Stock Exchange under code 4890, reported consolidated revenue of ¥491 million for the six months ended September 30, 2026, alongside an operating loss of ¥331 million, an ordinary loss of ¥294 mill...
Tsubota Laboratory Narrows Quarterly Loss as Revenue Surges and Eyes Full-Year Profit
Tsubota Laboratory reported a sharp increase in first-quarter revenue to ¥215 million, up more than eightfold year on year, while still posting a net loss of ¥134 million, which narrowed from the prior-year period. The company’s equity ratio declined...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 25, 2026